MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...

Der Abgang der Biontech-Gründer sorgte auch an der Börse für ein Beben. Doch große Fortschritte bei einem mRNA-Impfstoff ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call ...

BioNTech's personalized mRNA cancer vaccine posts striking 6-year survival data in pancreatic cancer, while its CureVac subsidiary files a new patent lawsuit against Moderna.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific ...

FRANKFURT (Reuters) -Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that ...

Bristol Myers Squibb and BioNTech announced a strategic partnership June 2 to co-develop and co-commercialize BioNTech’s next-generation cancer immunotherapy – BNT327 – across numerous solid tumor ...

BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally ...